REDX-10178
- Generic Name
- REDX-10178
Assess the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of RXC007 in Idiopathic Pulmonary Fibrosis
- First Posted Date
- 2022-10-06
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- Redx Pharma Plc
- Target Recruit Count
- 48
- Registration Number
- NCT05570058
- Locations
- 🇵🇱
Institute of Tuberculosis and Lung Diseases in Warsaw, Warsaw, Poland
🇨🇭University Hospital of Geneve, Geneva, Switzerland
🇮🇹Ospedale S. Giuseppe Milano, Milan, Italy
A 3-part Study to Evaluate Safety, Tolerability, Food Effect and Drug-drug Interactions of RXC007 in Healthy Volunteers
Phase 1
Completed
- Conditions
- InflammationIdiopathic Pulmonary FibrosisLiver DiseasesKidney DiseasesNon-alcoholic SteatohepatitisFibrosis
- Interventions
- Drug: RXC007 Matching Placebo
- First Posted Date
- 2021-06-18
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Redx Pharma Plc
- Target Recruit Count
- 90
- Registration Number
- NCT04931147
- Locations
- 🇬🇧
Simbec-Orion Clinical Pharmacology, Merthyr Tydfil, Mid Glamorgan, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath